Research Corporation Technologies, Inc. (RCT), a Tucson, Arizona-based technology investment and management company, has partnered with Cambridge, UK-based Isogenica, to access Isogenica's CIS display platform for the screening of proprietary libraries of a new antigen-binding protein scaffold.
The RCT libraries are part of a biologics discovery platform to identify engineered antibody fragments called Abdurins for development into therapeutic agents. Abdurins retain the desired long half-life of an antibody's CH2 domain and are engineered for enhanced stability, epitope binding and other properties.
To facilitate screening of the novel Abdurins libraries, RCT has partnered with Isogenica to provide interested parties access to their proprietary, high throughput display and screening platform called CIS display. CIS display can screen significantly larger libraries and isolate and optimize lead binders in a fraction of the time it takes using phage display. In addition to CIS display, Isogenica will support RCT through deep sequencing and related bioinformatics tools that can inform the optimisation of the selected Abdurins.
"Isogenica's CIS display offers a significant advantage over other screening systems by allowing for primary screening and binder optimization in one system. The pairing of CIS display with our Abdurins platform will be an attractive offering to potential partners," stated Dr Kurt Gehlsen, vice president and CSO of RCT.
Dr Kevin Matthews, CEO of Isogenica commented, "Our agreement with RCT underlines the value that CIS display brings to companies that are pioneering new antibody scaffolds for the development of better medicines. We look forward to supporting the deployment of RCT's Abdurins library and working with their biopharma collaborators to find new therapeutic candidates."
Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technology, CIS display.